News has been on the lighter side since our last update, typical for the end of year lull.
Biodesix initiated their 2000 patient ALTITUDE trial for the Nodify XL2 Lung Classifier. This first in class trial is intended to assess the clinical utility of Nodify XL2 in patients that have new incidentally identified solid lung masses with < 50% risk of cancer using the Mayo algorithm. The company is hopeful that the assay can reduce the number of invasive surgeries performed on patients with benign disease using this blood test.
